Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform.

Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA.

Cancer Immunol Res. 2020 Mar 17. pii: canimm.0745.2019. doi: 10.1158/2326-6066.CIR-19-0745. [Epub ahead of print]

PMID:
32184297
2.

ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Oh CY, Klatt MG, Bourne C, Dao T, Dacek MM, Brea EJ, Mun SS, Chang AY, Korontsvit T, Scheinberg DA.

Cancer Immunol Res. 2019 Dec;7(12):1984-1997. doi: 10.1158/2326-6066.CIR-19-0056. Epub 2019 Sep 20.

PMID:
31540894
3.

Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.

Dao T, Mun SS, Scott AC, Jarvis CA, Korontsvit T, Yang Z, Liu L, Klatt MG, Guerreiro M, Selvakumar A, Brea EJ, Oh C, Liu C, Scheinberg DA.

Oncoimmunology. 2019 Apr 15;8(7):1570778. doi: 10.1080/2162402X.2019.1570778. eCollection 2019.

4.

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Klatt MG, Kowalewski DJ, Schuster H, Di Marco M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanović S.

Oncoimmunology. 2016 Jun 30;5(8):e1204504. doi: 10.1080/2162402X.2016.1204504. eCollection 2016 Aug.

5.

The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells.

Kurachi M, Barnitz RA, Yosef N, Odorizzi PM, DiIorio MA, Lemieux ME, Yates K, Godec J, Klatt MG, Regev A, Wherry EJ, Haining WN.

Nat Immunol. 2014 Apr;15(4):373-83. doi: 10.1038/ni.2834. Epub 2014 Mar 2.

Supplemental Content

Loading ...
Support Center